Stock listing
NASDAQ:INBX Inhibrx Biosciences, Inc. Stock
Home listing (NASDAQ) of Inhibrx Biosciences, Inc.
Follow Inhibrx Biosciences, Inc. into a list and get an email when it puts out news.
Share price · NASDAQ:INBX
$68.97 USD -0.09 (-0.1%)
Close on Nov 20, 2026
- Day range
- $68.78 – $74.45 USDNov 20, 2026
- Volume
- 252,126 sharesNov 20, 2026
- Market cap
- $1.02B USDAt the close on Nov 20, 2026 · price × 14.72M shares outstanding
- 52-week range
- $57.30 – $155.29 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $29.86M USDMedian day 242,218 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:INBX · Home | $68.97 USD | -0.09 (-0.1%) | 252,126 | $72.72 | $74.45 | $68.78 | $69.06 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:INBX · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $68.97 | -0.09 | -0.1% | $72.72 | $74.45 | $68.78 | 252,126 | |
| $69.06 | -5.12 | -6.9% | $74.21 | $75.42 | $68.27 | 288,906 | |
| $74.18 | -3.48 | -4.5% | $78.21 | $78.21 | $72.95 | 300,129 | |
| $77.66 | -5.64 | -6.8% | $80.28 | $84.71 | $76.50 | 286,042 | |
| $83.30 | -4.445 | -5.1% | $87.91 | $87.91 | $80.95 | 245,896 | |
| $87.75 | -2.845 | -3.1% | $88.56 | $91.13 | $86.00 | 226,482 | |
| $90.59 | -0.02 | 0.0% | $92.38 | $93.48 | $89.39 | 165,638 | |
| $90.61 | -1.13 | -1.2% | $90.31 | $92.90 | $90.01 | 100,296 | |
| $91.74 | +7.22 | +8.5% | $86.40 | $93.45 | $84.83 | 185,736 | |
| $84.52 | +4.24 | +5.3% | $80.68 | $85.57 | $79.47 | 220,135 | |
| $80.28 | -6.48 | -7.5% | $86.00 | $86.75 | $79.35 | 242,218 | |
| $86.76 | +5.68 | +7.0% | $83.95 | $87.13 | $82.13 | 190,181 | |
| $81.08 | +8.92 | +12.4% | $71.16 | $83.00 | $71.16 | 600,229 | |
| $72.16 | +0.38 | +0.5% | $72.45 | $73.49 | $70.87 | 234,349 | |
| $71.78 | -1.87 | -2.5% | $72.04 | $73.03 | $66.80 | 438,800 | |
| $73.65 | +0.36 | +0.5% | $73.75 | $75.72 | $71.75 | 358,700 | |
| $73.29 | -22.37 | -23.4% | $94.55 | $96.79 | $69.27 | 1,188,600 | |
| $95.66 | +7.05 | +8.0% | $88.52 | $99.88 | $88.52 | 373,900 | |
| $88.61 | -4.77 | -5.1% | $93.80 | $94.46 | $86.92 | 251,200 | |
| $93.38 | -3.72 | -3.8% | $96.96 | $96.99 | $92.50 | 176,200 | |
| $97.10 | -1.09 | -1.1% | $96.94 | $100.20 | $94.04 | 249,500 | |
| $98.19 | +2.89 | +3.0% | $98.10 | $99.82 | $93.00 | 239,300 | |
| $95.30 | +5.51 | +6.1% | $89.07 | $96.50 | $88.99 | 221,400 | |
| $89.79 | -0.04 | 0.0% | $90.43 | $92.98 | $88.21 | 156,100 | |
| $89.83 | -0.67 | -0.7% | $89.83 | $90.72 | $87.73 | 146,400 | |
| $90.50 | +5.24 | +6.1% | $87.60 | $91.68 | $87.20 | 226,400 | |
| $85.26 | -1.82 | -2.1% | $86.23 | $87.36 | $83.61 | 246,100 | |
| $87.08 | -3.45 | -3.8% | $90.11 | $92.46 | $85.80 | 271,300 | |
| $90.53 | -4.48 | -4.7% | $94.03 | $96.10 | $90.00 | 216,100 | |
| $95.01 | +2.25 | +2.4% | $92.70 | $95.81 | $92.70 | 86,800 | |
| $92.76 | -0.60 | -0.6% | $93.14 | $93.28 | $90.15 | 208,000 | |
| $93.36 | -0.05 | -0.1% | $92.02 | $96.71 | $90.66 | 223,800 | |
| $93.41 | -1.15 | -1.2% | $95.52 | $96.96 | $92.60 | 169,400 | |
| $94.56 | -2.43 | -2.5% | $97.56 | $98.51 | $94.18 | 206,900 | |
| $96.99 | -0.94 | -1.0% | $99.30 | $100.13 | $96.07 | 201,400 | |
| $97.93 | -2.15 | -2.1% | $100.71 | $102.16 | $97.58 | 216,600 | |
| $100.08 | -4.75 | -4.5% | $105.67 | $106.94 | $100.08 | 389,500 | |
| $104.83 | +3.12 | +3.1% | $105.31 | $107.90 | $102.51 | 240,900 | |
| $101.71 | +2.10 | +2.1% | $98.69 | $104.55 | $98.51 | 188,100 | |
| $99.61 | -0.79 | -0.8% | $101.29 | $101.29 | $98.09 | 158,700 | |
| $100.40 | +0.07 | +0.1% | $102.38 | $104.49 | $99.53 | 285,700 | |
| $100.33 | -10.34 | -9.3% | $110.12 | $110.88 | $98.56 | 375,300 | |
| $110.67 | -1.37 | -1.2% | $112.45 | $117.14 | $109.05 | 292,100 | |
| $112.04 | +2.69 | +2.5% | $112.69 | $113.19 | $108.95 | 249,100 | |
| $109.35 | +4.62 | +4.4% | $106.45 | $110.41 | $105.04 | 483,400 | |
| $104.73 | +2.96 | +2.9% | $103.73 | $108.00 | $103.73 | 216,600 | |
| $101.77 | -3.84 | -3.6% | $105.61 | $106.44 | $99.06 | 363,500 | |
| $105.61 | -4.86 | -4.4% | $109.44 | $109.44 | $104.85 | 251,600 | |
| $110.47 | +1.20 | +1.1% | $109.10 | $111.44 | $104.90 | 240,000 | |
| $109.27 | -2.15 | -1.9% | $113.00 | $115.11 | $108.93 | 211,000 | |
| $111.42 | -1.44 | -1.3% | $109.23 | $113.95 | $107.22 | 313,900 | |
| $112.86 | -1.48 | -1.3% | $117.38 | $128.54 | $112.03 | 677,800 | |
| $114.34 | -6.83 | -5.6% | $117.22 | $120.18 | $94.00 | 1,672,200 | |
| $121.17 | -1.09 | -0.9% | $121.04 | $124.19 | $120.48 | 194,600 | |
| $122.26 | -2.71 | -2.2% | $125.20 | $126.00 | $120.17 | 151,700 | |
| $124.97 | +0.31 | +0.2% | $125.61 | $127.75 | $121.25 | 189,900 | |
| $124.66 | -2.04 | -1.6% | $124.98 | $129.88 | $120.62 | 275,600 | |
| $126.70 | +3.29 | +2.7% | $123.39 | $128.87 | $121.59 | 389,000 | |
| $123.41 | -0.52 | -0.4% | $123.80 | $126.04 | $119.38 | 241,500 | |
| $123.93 | -1.41 | -1.1% | $124.27 | $127.34 | $122.36 | 310,900 | |
| $125.34 | +2.62 | +2.1% | $123.00 | $131.01 | $119.44 | 302,900 | |
| $122.72 | +17.78 | +16.9% | $105.50 | $126.50 | $104.71 | 510,600 | |
| $104.94 | +1.31 | +1.3% | $105.00 | $105.14 | $94.20 | 373,500 | |
| $103.63 | +4.48 | +4.5% | $100.76 | $105.65 | $99.05 | 220,700 | |
| $99.15 | -2.33 | -2.3% | $98.65 | $102.50 | $96.57 | 351,500 |
- Ticker
- NASDAQ:INBX
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Currency
- USD
What changed lately
Latest news release · Nov 17, 2026
Inhibrx Announces Updated Clinical Data for Ozekibart (INBRX-109) in Ewing Sarcoma
Latest deck · Nov 13, 2026
Investor Presentation (November 2026)
Investor deck · 44 slides
Latest news
Inhibrx Announces Updated Clinical Data for Ozekibart (INBRX-109) in Ewing Sarcoma
Nov 17, 2026
Closed $69.06 (-6.9%) on Nov 18, 2026
Inhibrx Reports Third Quarter 2026 Financial Results
Nov 13, 2026
Closed $77.66 (-6.8%) on Nov 16, 2026
Inhibrx Announces Participation in Upcoming Scientific Conferences
Oct 13, 2026
Closed $85.26 (-2.1%) on Oct 14, 2026
Inhibrx's INBRX-106 Nearly Doubles Response Rate and Achieves Interim Median PFS of 9.6 months in Phase 2 HNSCC Study
Sep 8, 2026
Closed $114.34 (-5.6%) on Sep 8, 2026
Inhibrx To Host Webcast Presentation to Provide Primary Endpoint Results for INBRX-106 Phase 2 First-Line HNSCC Study
Sep 4, 2026
Closed $114.34 (-5.6%) on Sep 8, 2026
Inhibrx Reports Second Quarter 2026 Financial Results
Aug 13, 2026
Closed $88.37 (-8.9%) on Aug 14, 2026
Inhibrx Biosciences Announces Amended Loan Agreement with Oxford Finance, Expanding Total Facility to $500.0 Million
Jul 16, 2026
Closed $89.07 (-2.4%) on Jul 16, 2026
Inhibrx Announces U.S. FDA Acceptance of BLA for Ozekibart in Patients with Conventional Chondrosarcoma
Jun 15, 2026
Closed $93.51 (+1.4%) on Jun 15, 2026
Inhibrx Reports First Quarter 2026 Financial Results
May 14, 2026
Closed $108.64 (-6.5%) on May 15, 2026
Inhibrx Biosciences, Inc. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 16 in the last 12 months · 26 in all · newest Nov 17, 2026 · oldest 2024
- Decks
- 36 decks · latest Nov 13, 2026
Where Inhibrx Biosciences, Inc. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:INBX · Home listing · This page | NASDAQ | United States | USD |
| BOATS:INBX | BOATS | United States | USD |
Valuation
EV/sales 546× against a median of 9.3×: the highest of 9 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- $1.09B USD
- P/E
- Loss
- EV/sales
- 546×
- EV/EBITDA
- Negative EBITDA
- Price/book
- Negative equity
- Gross margin
- Revenue too small
- Operating margin
- Revenue too small
- Net margin
- Revenue too small
- Debt to equity
- Negative equity
- Beta vs S&P 500
- 1.89
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Inhibrx Biosciences, Inc. · NASDAQ:INBX | US$1.02B | US$1.09B | n/a | 546× | n/a | n/a | n/a | n/a | 1.89 |
| MedinCell SA · EURONEXT:MEDCL | US$1.05B | US$1.02B | n/a | 38.4× | n/a | 313× | −128.9% | 18.7× | n/a |
| Nektar Therapeutics · NASDAQ:NKTR | US$1.03B | US$492.8M | n/a | 9.4× | n/a | 1.2× | −339.7% | 0.1× | 1.28 |
| Mabwell (Shanghai) Bioscience Co., Ltd. Class A · SSE:688062 | US$1.02B | US$984.8M | n/a | 9.2× | n/a | 9.5× | −146.4% | 2.9× | n/a |
| SpyGlass Pharma, Inc. · NASDAQ:SGP | US$1.02B | US$809.5M | n/a | n/a | n/a | 4.8× | n/a | 0.0× | 1.01 |
| Alto Neuroscience, Inc. · NYSE:ANRO | US$1.02B | US$711.7M | n/a | n/a | n/a | 3.4× | n/a | 0.1× | 1.65 |
| Duality Biotherapeutics, Inc. · HKEX:9606 | US$992.3M | US$609.0M | n/a | 4.8× | n/a | 4.6× | −170.8% | 0.3× | n/a |
| Peptron, Inc. · KRX:087010 | US$985.3M | US$948.0M | n/a | 211× | n/a | 10.2× | −342.2% | 0.2× | n/a |
| Omeros Corporation · NASDAQ:OMER | US$983.7M | US$920.3M | 10.0× | 12.4× | n/a | n/a | 132.3% | n/a | 1.64 |
| Everest Medicines Ltd. · HKEX:1952 | US$981.5M | US$1.00B | n/a | 2.8× | 183× | 1.3× | −2.2% | 0.4× | n/a |
| HBM Holdings Ltd. · HKEX:2142 | US$981.4M | US$711.5M | 10.7× | 4.5× | 8.6× | 2.4× | 57.8% | 0.2× | n/a |
| Median of the others | US$1.00B | US$864.9M | 10.4× | 9.3× | 95.9× | 4.6× | −137.6% | 0.2× | 1.46 |
Forecasts
3 strong buy · 1 hold · Analysts' consensus from EODHD, read Nov 15, 2026. Not 6ix's view and not investment advice.
- Price target
- 266.67 USD · Analysts' mean
- EPS, year to Dec 2026
- -9.26 · 2 analysts
Team and board
Officers
| Officer | Role |
|---|---|
| Mark P. Lappe | Founder, Chief Executive Officer |
| Kelly Deck | EVP, Chief Financial Officer |
| David Matly | President |
| Leah Pollema | VP, General Counsel |
| Ashraf Amanullah | EVP, Chief Technical Operations Officer |
| Bonne Adams | VP, Operations |
| Brian Lobo | VP, Formulation Development and Drug Product Manufacturing |
| Carlos Bais | EVP, Chief Scientific Officer |
| Dana Ebbets-Reed | VP, Quality Assurance |
| Darren Brown | VP, Analytical Development and Quality Control |
| David Kao | VP, Regulatory Affairs |
| Josep Garcia | EVP, Chief Clinical Development Officer |
| Kate Burke C.P.A. | VP, Accounting |
| Melissa Masterson | VP, Access and Commercialization |
| Robert Boothroyd | VP, Medical Affairs and Business Development |
| Sean Flanagan | VP, Sales |
Board
| Director | Role |
|---|---|
| Mark P. Lappe | Founder, Chief Executive Officer |
| Douglas G. Forsyth | Director |
| Jon Faiz Kayyem | Director |
| Kimberly Manhard | Director |
| Kristiina Vuori | Director |
Events
| Quarter | Results | Share move |
|---|---|---|
| Q3 2026 | Nov 13, 2026 · After close | −6.8% |
| Q2 2026 | Aug 13, 2026 · After close | −8.9% |
| Q1 2026 | May 14, 2026 · After close | −6.5% |
| Q4 2025 | Mar 23, 2026 | +3.6% |
| Q3 2025 | Nov 14, 2025 · Before open | +6.0% |
| Q2 2025 | Aug 13, 2025 · After close | +1.6% |
| Q1 2025 | May 14, 2025 · After close | +10.9% |
| Q4 2024 | Mar 17, 2025 | −0.7% |
| Q3 2024 | Nov 14, 2024 · After close | −3.5% |
| Q2 2024 | Aug 13, 2024 | +0.4% |
All 11 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q1 2024 | May 29, 2024 |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (November 2026) | Investor deck | 44 slides | Nov 13, 2026 |
| Technical Presentation (October 2026) | Technical | 16 slides | Oct 25, 2026 |
| Investor Presentation (September 2026) | Investor deck | 44 slides | Sep 28, 2026 |
| Investor Presentation (September 2026) | Investor deck | 40 slides | September 2026 |
| Investor Presentation (September 2026) | Investor deck | 26 slides | September 2026 |
| Investor Presentation (September 2026) | Investor deck | 24 slides | September 2026 |
| Investor Presentation (August 2026) | Investor deck | 28 slides | August 2026 |
| Investor Presentation (June 2026) | Investor deck | 27 slides | June 2026 |
| Investor Presentation (April 2026) | Investor deck | 27 slides | Apr 21, 2026 |
| Investor Presentation (March 2026) | Investor deck | 26 slides | March 2026 |
All 36 decks
Financings
| Raise | Date |
|---|---|
| Term C Loan with warrants Closed: US$100M raised · Warrants at US$93.21 for 120 months Buyers: Oxford Finance LLC (funded the $100.0 million Term C Loan and received warrants to purchase 21,457 shares) Use of proceeds: Advancing the ozekibart (INBRX-109) and INBRX-106 programs | Jul 16, 2026 |
Open Financings · Read by 6ix AI from the company's releases
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.30M | 200.0K | 1.80M | 2.19M | 7.13M | 12.8M | 9.09M | 8.60M | 8.39M | 6.67M |
| Cost of revenue | 2.48M | 2.29M | 1.19M | 110.2M | 2.69M | 73.5M | 47.9M | 33.5M | 25.5M | 17.0M |
| Gross profit | -1.18M | -2.08M | 609.0K | -108.0M | 4.44M | -60.7M | -38.8M | -24.9M | -17.1M | -10.3M |
| Research and development | 113.0M | 203.7M | 191.6M | 110.2M | 71.4M | 73.5M | 47.9M | 33.5M | 25.5M | 17.0M |
| Selling, general and administrative | 23.3M | 127.9M | 29.4M | 21.1M | 12.4M | 6.84M | 9.02M | 4.65M | 2.61M | 1.82M |
| Operating income | -135.0M | -331.4M | -219.2M | -129.1M | -76.7M | -67.4M | -41.0M | -29.5M | -19.7M | -12.1M |
| Depreciation and amortization | 2.48M | 2.29M | 1.19M | 1.23M | 1.20M | 1.02M | 1.16M | 676.0K | 399.0K | 253.0K |
| EBITDA | -132.5M | -329.2M | -218.0M | -127.9M | -75.5M | -66.4M | -39.8M | -28.8M | -19.3M | -11.9M |
| Interest expense | 12.2M | 13.5M | 31.8M | 16.1M | 5.22M | 10.8M | 5.72M | 1.48M | 2.13M | |
| Income before tax | -140.1M | 1.69B | -239.7M | -145.2M | -81.8M | -75.6M | -50.5M | -30.9M | -21.8M | -12.9M |
| Income tax | 2.00K | 2.00K | 3.00K | 3.00K | 2.00K | 3.00K | 898.0K | 96.0K | 250.0K | -4.62M |
| Net income | -140.1M | 1.69B | -241.4M | -145.2M | -81.8M | -76.1M | -51.4M | -31.2M | -19.4M | -8.27M |
| Earnings per share, basic | -9.04 | 114.01 | -20.48 | -3.62 | -2.15 | -3.01 | -1.41 | -1.15 | -0.68 | -0.23 |
| Earnings per share, diluted | -9.04 | 112.62 | -20.48 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 124.2M | 152.6M | 277.9M | 273.9M | 131.3M | 128.7M | 11.5M | 2.10M | 13.5M | 20.0M |
| Receivables | 177.0K | 420.0K | 778.0K | 257.0K | 878.0K | 615.0K | 438.0K | 690.0K | 696.0K | |
| Inventory | -257.0K | -878.0K | -129.3M | 3.21M | 2.31M | 999.0K | ||||
| Current assets | 132.8M | 160.4M | 295.4M | 280.5M | 139.1M | 132.2M | 15.6M | 5.66M | 15.4M | 20.4M |
| Property, plant and equipment | 3.73M | 6.20M | 6.42M | |||||||
| Total assets | 146.5M | 180.8M | 307.9M | 290.9M | 150.4M | 143.7M | 26.5M | 9.98M | 17.2M | 21.3M |
| Accounts payable | 5.94M | 9.24M | 11.0M | 8.33M | 9.13M | 13.5M | 3.12M | 6.53M | 775.0K | 167.0K |
| Current liabilities | 33.8M | 40.7M | 56.3M | 27.6M | 22.5M | 31.4M | 20.6M | 16.2M | 8.92M | 5.28M |
| Long-term debt | 100.6M | 0 | 207.0M | |||||||
| Total debt | 100.6M | 0 | 207.0M | 207.1M | 72.1M | 37.5M | 41.7M | 9.49M | 14.7M | 18.9M |
| Total liabilities | 138.5M | 47.2M | 264.4M | 232.8M | 98.1M | 68.3M | 120.1M | 67.6M | 39.7M | 20.0M |
| Shareholders' equity | 7.99M | 133.6M | 43.5M | 58.1M | 52.4M | 75.5M | -93.6M | -57.6M | -28.8M | -9.25M |
| Shares outstanding | 14.6M | 14.5M | 47.4M | 40.1M | 38.0M | 25.3M | 36.6M | 27.1M | 28.8M | 36.6M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | -129.8M | -194.4M | -193.3M | -115.3M | -80.3M | -48.0M | -32.1M | -23.1M | -18.8M | -18.1M |
| Capital spending | -31.0K | -2.60M | -4.59M | -686.0K | -864.0K | -1.36M | -1.81M | -1.43M | -1.34M | -215.0K |
| Free cash flow | -129.8M | -197.0M | -197.9M | -116.0M | -81.2M | -49.3M | -33.9M | -24.5M | -20.1M | -18.3M |
| Cash from investing | -28.0K | -2.60M | -4.59M | -686.0K | -809.0K | -1.36M | -1.81M | -1.43M | -1.34M | -215.0K |
| Cash from financing | 101.4M | 71.7M | 202.0M | 258.6M | 83.8M | 166.5M | 43.3M | 13.2M | 13.5M | 28.8M |
| Dividends paid | -828.0K | -1.38M | ||||||||
| Share buybacks | -340.0K | |||||||||
| Change in cash | -28.4M | -125.3M | 4.06M | 142.6M | 2.64M | 117.1M | 9.44M | -11.4M | -6.55M | 10.4M |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 8-K · Current report | Nov 17, 2026 | Current report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 13, 2026 | Big-stake notice | SEC |
| S-3ASR · Registration statement | Nov 13, 2026 | Offer document | SEC |
| 10-Q · Quarterly report | Nov 13, 2026 | Quarterly report | SEC |
| 8-K · Current report | Nov 13, 2026 | Results | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Oct 28, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Oct 14, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Sep 28, 2026 | Insider trade | SEC |
| 8-K · Current report | Sep 28, 2026 | Current report | SEC |
| 4 · Change in ownership | Sep 23, 2026 | Insider trade | SEC |
All 163 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 4/A · Change in ownership, amended | Sep 18, 2026 | Insider trade | SEC |
| 4/A · Change in ownership, amended | Sep 18, 2026 | Insider trade | SEC |
| 4/A · Change in ownership, amended | Sep 18, 2026 | Insider trade | SEC |
| 4/A · Change in ownership, amended | Sep 18, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Sep 17, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Sep 15, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Sep 15, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Sep 14, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Sep 11, 2026 | Other filings | SEC |
| 4 · Change in ownership | Sep 10, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Sep 9, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Sep 8, 2026 | Other filings | SEC |
| 4 · Change in ownership | Sep 8, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Sep 8, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Sep 8, 2026 | Insider trade | SEC |
| 8-K · Current report | Sep 8, 2026 | Current report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 14, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Aug 14, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 14, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Aug 13, 2026 | Results | SEC |
| 10-Q · Quarterly report | Aug 13, 2026 | Quarterly report | SEC |
| SCHEDULE 13G · Big-stake notice | Aug 3, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Jul 16, 2026 | Material contract | SEC |
| 8-K · Current report | Jun 15, 2026 | Current report | SEC |
| 4 · Change in ownership | Jun 4, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 4, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 4, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 4, 2026 | Insider trade | SEC |
| 8-K · Current report | Jun 3, 2026 | Meeting outcome | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 15, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 15, 2026 | Big-stake notice | SEC |
| 8-K · Current report | May 14, 2026 | Results | SEC |
| 10-Q · Quarterly report | May 14, 2026 | Quarterly report | SEC |
| 8-K · Current report | May 11, 2026 | Current report | SEC |
| 4 · Change in ownership | Apr 27, 2026 | Insider trade | SEC |
| ARS · Annual report to shareholders | Apr 23, 2026 | Annual report | SEC |
| DEFA14A · Additional proxy material | Apr 23, 2026 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 23, 2026 | Meeting notice | SEC |
| 8-K · Current report | Apr 21, 2026 | Current report | SEC |
| 8-K · Current report | Mar 19, 2026 | Results | SEC |
| 10-K · Annual report | Mar 19, 2026 | Annual report | SEC |
| 8-K · Current report | Feb 23, 2026 | Current report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 17, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Feb 11, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Jan 21, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Dec 16, 2025 | Current report | SEC |
| 8-K · Current report | Nov 13, 2025 | Results | SEC |
| 10-Q · Quarterly report | Nov 13, 2025 | Quarterly report | SEC |
| 8-K · Current report | Oct 23, 2025 | Current report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Oct 17, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Oct 9, 2025 | Insider trade | SEC |
| 8-K · Current report | Aug 13, 2025 | Results | SEC |
| 10-Q · Quarterly report | Aug 13, 2025 | Quarterly report | SEC |
| EFFECT · Notice that a registration is effective | Jun 5, 2025 | Other filings | SEC |
| POS AM · Amendment to an effective registration | Jun 2, 2025 | Offer document | SEC |
| 4 · Change in ownership | May 29, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 29, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 29, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 29, 2025 | Insider trade | SEC |
| 424B3 · Prospectus | May 28, 2025 | Offer document | SEC |
| 8-K · Current report | May 28, 2025 | Meeting outcome | SEC |
| 424B3 · Prospectus | May 14, 2025 | Offer document | SEC |
| 8-K · Current report | May 14, 2025 | Results | SEC |
| 10-Q · Quarterly report | May 14, 2025 | Quarterly report | SEC |
| EFFECT · Notice that a registration is effective | Apr 21, 2025 | Other filings | SEC |
| POS AM · Amendment to an effective registration | Apr 17, 2025 | Offer document | SEC |
| ARS · Annual report to shareholders | Apr 16, 2025 | Annual report | SEC |
| DEFA14A · Additional proxy material | Apr 16, 2025 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 16, 2025 | Meeting notice | SEC |
| 4 · Change in ownership | Apr 2, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Apr 2, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Apr 2, 2025 | Insider trade | SEC |
| 424B3 · Prospectus | Apr 1, 2025 | Offer document | SEC |
| 8-K · Current report | Apr 1, 2025 | Management or board change | SEC |
| 4 · Change in ownership | Mar 28, 2025 | Insider trade | SEC |
| POS EX | Mar 17, 2025 | Other filings | SEC |
| 424B3 · Prospectus | Mar 17, 2025 | Offer document | SEC |
| 8-K · Current report | Mar 17, 2025 | Results | SEC |
| 10-K · Annual report | Mar 17, 2025 | Annual report | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Feb 26, 2025 | Big-stake notice | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Feb 26, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Feb 4, 2025 | Big-stake notice | SEC |
| 424B3 · Prospectus | Jan 21, 2025 | Offer document | SEC |
| 8-K · Current report | Jan 21, 2025 | Current report | SEC |
| 424B3 · Prospectus | Jan 13, 2025 | Offer document | SEC |
| 8-K · Current report | Jan 13, 2025 | Material contract | SEC |
| 4 · Change in ownership | Dec 17, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Dec 6, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Nov 22, 2024 | Insider trade | SEC |
| SC 13G · Big-stake notice | Nov 14, 2024 | Big-stake notice | SEC |
| 424B3 · Prospectus | Nov 14, 2024 | Offer document | SEC |
| 8-K · Current report | Nov 14, 2024 | Results | SEC |
| 10-Q · Quarterly report | Nov 14, 2024 | Quarterly report | SEC |
| 424B3 · Prospectus | Nov 4, 2024 | Offer document | SEC |
| 8-K · Current report | Nov 4, 2024 | Current report | SEC |
| 4 · Change in ownership | Oct 7, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Sep 16, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Sep 12, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Sep 10, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Sep 3, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Sep 3, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Aug 30, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Aug 26, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Aug 22, 2024 | Insider trade | SEC |
| 424B3 · Prospectus | Aug 14, 2024 | Offer document | SEC |
| 424B3 · Prospectus | Aug 13, 2024 | Offer document | SEC |
| 8-K · Current report | Aug 13, 2024 | Results | SEC |
| 10-Q · Quarterly report | Aug 13, 2024 | Quarterly report | SEC |
| 4 · Change in ownership | Jun 24, 2024 | Insider trade | SEC |
| EFFECT · Notice that a registration is effective | Jun 20, 2024 | Other filings | SEC |
| 424B3 · Prospectus | Jun 18, 2024 | Offer document | SEC |
| 8-K · Current report | Jun 17, 2024 | Current report | SEC |
| CORRESP · Letter to the SEC | Jun 14, 2024 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Jun 14, 2024 | Other filings | SEC |
| S-1 · Registration statement | Jun 11, 2024 | Offer document | SEC |
| 4 · Change in ownership | Jun 7, 2024 | Insider trade | SEC |
| SC 13G · Big-stake notice | Jun 7, 2024 | Big-stake notice | SEC |
| 3 · Initial statement of ownership | Jun 7, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 4, 2024 | Insider trade | SEC |
| SC 13D · Big-stake notice | Jun 3, 2024 | Big-stake notice | SEC |
| SC 13D · Big-stake notice | Jun 3, 2024 | Big-stake notice | SEC |
| SC 13G · Big-stake notice | May 31, 2024 | Big-stake notice | SEC |
| 4 · Change in ownership | May 31, 2024 | Insider trade | SEC |
| 4 · Change in ownership | May 30, 2024 | Insider trade | SEC |
| 4 · Change in ownership | May 30, 2024 | Insider trade | SEC |
| 4 · Change in ownership | May 30, 2024 | Insider trade | SEC |
| 4 · Change in ownership | May 30, 2024 | Insider trade | SEC |
| 4 · Change in ownership | May 30, 2024 | Insider trade | SEC |
| 4 · Change in ownership | May 30, 2024 | Insider trade | SEC |
| 4 · Change in ownership | May 30, 2024 | Insider trade | SEC |
| S-8 · Registration statement for employee plans | May 30, 2024 | Offer document | SEC |
| 8-K · Current report | May 30, 2024 | Material contract | SEC |
| 3 · Initial statement of ownership | May 24, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | May 24, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | May 24, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | May 24, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | May 24, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | May 24, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | May 24, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | May 24, 2024 | Insider trade | SEC |
| 8-K · Current report | May 24, 2024 | Current report | SEC |
| SEC STAFF ACTION | May 24, 2024 | Other filings | SEC |
| CERT · Exchange's certificate of listing | May 24, 2024 | Other filings | SEC |
| CORRESP · Letter to the SEC | May 22, 2024 | Other filings | SEC |
| 10-12B/A | May 15, 2024 | Other filings | SEC |
| 10-12B/A | May 8, 2024 | Other filings | SEC |
| CORRESP · Letter to the SEC | Apr 25, 2024 | Other filings | SEC |
| 10-12B | Apr 25, 2024 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Apr 4, 2024 | Other filings | SEC |
| DRSLTR · Letter to the SEC with a draft | Mar 4, 2024 | Other filings | SEC |
| DRS/A · Draft registration statement, amended | Mar 4, 2024 | Offer document | SEC |
| UPLOAD · Letter from the SEC | Feb 29, 2024 | Other filings | SEC |
| DRS · Draft registration statement | Jan 26, 2024 | Offer document | SEC |
Cap table
Built by 6ix from Inhibrx Biosciences, Inc.’s releases · as of Aug 7, 2026
- Common shares
- 14,717,660
- Fully diluted
- 14,717,660
Fully diluted
| Line | Shares | As of |
|---|---|---|
| Common shares | 14,717,660 | Aug 7, 2026 |
Warrants and options
| Lot |
|---|
| Warrants · US$93.21 · expire about Jul 2036 |
Share count over time
| Count | Shares |
|---|---|
| Aug 7, 2026 | 14,717,660 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Kimberly Manhard Other companies: Connect Biopharma Holdings Limited (CHIEF DEVELOPMENT OFFICER · Since at least Nov 5, 2026); Inhibrx Inc (Director · Aug 18, 2020 – May 30, 2024 · Past); Heron Therapeutics, Inc. (EVP, Drug Development · Jan 10, 2014 – Apr 13, 2023 · Past); Ardea Biosciences Inc (SVP, Regulatory & Dev Ops · Oct 28, 2011 – Jun 19, 2012 · Past) | Director · Since at least May 24, 2024 |
| Jon Faiz Kayyem Other companies: Biodesix, Inc. (Director · Since at least Jan 1, 2024); Inhibrx Inc (Director · May 30, 2024 – May 30, 2024 · Past) | Director · Since at least May 24, 2024 |
| Mark P. Lappe Other companies: Inhibrx Inc (Chief Executive Officer, Director · Aug 18, 2020 – May 30, 2024 · Past); Repros Therapeutics (Director · Sep 29, 2008 – May 20, 2009 · Past) | Founder, Chief Executive Officer · Since at least May 24, 2024 |
| Brendan P Eckelman Other companies: Inhibrx Inc (Chief Scientific Officer · Aug 18, 2020 – May 28, 2024 · Past) | Chief Scientific Officer · May 24, 2024 – May 29, 2024 · Past |
| Douglas G. Forsyth Other companies: Inhibrx Inc (Director · Aug 18, 2020 – May 30, 2024 · Past) | Director · Since at least May 24, 2024 |
| Ashraf Amanullah | EVP, Chief Technical Operations Officer · Since at least Nov 5, 2026 |
| Bonne Adams | VP, Operations · Since at least Nov 5, 2026 |
| Brian Lobo | VP, Formulation Development and Drug Product Manufacturing · Since at least Nov 5, 2026 |
| Carlos Bais | EVP, Chief Scientific Officer · Since at least Apr 1, 2025 |
| Dana Ebbets-Reed | VP, Quality Assurance · Since at least Nov 5, 2026 |
All 22 people
| Person | Seat |
|---|---|
| Darren Brown | VP, Analytical Development and Quality Control · Since at least Nov 5, 2026 |
| David Kao | VP, Regulatory Affairs · Since at least Nov 5, 2026 |
| David Matly | President · Since at least Apr 1, 2025 |
| Jon Faiz Kayyem | Director · Since at least Sep 23, 2026 |
| Josep Garcia | EVP, Chief Clinical Development Officer · Since at least Nov 4, 2025 |
| Kate Burke C.P.A. | VP, Accounting · Since at least Nov 4, 2026 |
| Kelly Deck | EVP, Chief Financial Officer · Since at least Apr 1, 2025 |
| Kristiina Vuori | Director · Since at least Nov 5, 2026 |
| Leah Pollema | VP, General Counsel · Since at least Nov 5, 2026 |
| Melissa Masterson | VP, Access and Commercialization · Since at least Nov 5, 2026 |
| Robert Boothroyd | VP, Medical Affairs and Business Development · Since at least Nov 5, 2026 |
| Sean Flanagan | VP, Sales · Since at least Nov 5, 2026 |
Log in to ask 6ix AI your own questions about Inhibrx Biosciences, Inc.